Literature DB >> 25806209

Antiangiogenic tyrosine kinase inhibitors in non-small-cell-lung cancer: lights and shadows.

Giampietro Gasparini1.   

Abstract

Entities:  

Year:  2013        PMID： 25806209      PMCID： PMC4367636          DOI： 10.3978/j.issn.2218-6751.2012.08.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  10 in total

Review 1.  Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.

Authors:  Giampietro Gasparini; Raffaele Longo; Massimo Fanelli; Beverly A Teicher
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

2.  Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

Authors:  Giorgio Scagliotti; Silvia Novello; Joachim von Pawel; Martin Reck; José Rodrigues Pereira; Michael Thomas; José Elias Abrão Miziara; Beatrix Balint; Filippo De Marinis; Alan Keller; Osvaldo Arén; Maria Csollak; Istvan Albert; Carlos Henrique Barrios; Francesco Grossi; Maciej Krzakowski; Lisa Cupit; Frank Cihon; Sandra Dimatteo; Nasser Hanna
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

Review 3.  Challenges for patient selection with VEGF inhibitors.

Authors:  R Longo; G Gasparini
Journal:  Cancer Chemother Pharmacol       Date:  2007-03-17       Impact factor: 3.333

4.  Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.

Authors:  F Pezzella; U Pastorino; E Tagliabue; S Andreola; G Sozzi; G Gasparini; S Menard; K C Gatter; A L Harris; S Fox; M Buyse; S Pilotti; M Pierotti; F Rilke
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

5.  Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

Authors:  Sean Tracy; Toru Mukohara; Mark Hansen; Matthew Meyerson; Bruce E Johnson; Pasi A Jänne
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

6.  International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

Authors:  Giorgio V Scagliotti; Ihor Vynnychenko; Keunchil Park; Yukito Ichinose; Kaoru Kubota; Fiona Blackhall; Robert Pirker; Rinat Galiulin; Tudor-Eliade Ciuleanu; Oleksandr Sydorenko; Mircea Dediu; Zsolt Papai-Szekely; Natividad Martinez Banaclocha; Sheryl McCoy; Bin Yao; Yong-Jiang Hei; Francesco Galimi; David R Spigel
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

7.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Authors:  Roy S Herbst; Giuseppe Giaccone; Joan H Schiller; Ronald B Natale; Vincent Miller; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Ira Oliff; James A Reeves; Michael K Wolf; Annetta D Krebs; Steven D Averbuch; Judith S Ochs; John Grous; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

8.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

9.  Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

Authors:  Richard H de Boer; Óscar Arrieta; Chih-Hsin Yang; Maya Gottfried; Valorie Chan; Johann Raats; Filippo de Marinis; Raymond P Abratt; Jürgen Wolf; Fiona H Blackhall; Peter Langmuir; Tsveta Milenkova; Jessica Read; Johan F Vansteenkiste
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

10.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Authors:  Roy S Herbst; Yan Sun; Wilfried E E Eberhardt; Paul Germonpré; Nagahiro Saijo; Caicun Zhou; Jie Wang; Longyun Li; Fairooz Kabbinavar; Yukito Ichinose; Shukui Qin; Li Zhang; Bonne Biesma; John V Heymach; Peter Langmuir; Sarah J Kennedy; Hiroomi Tada; Bruce E Johnson
Journal:  Lancet Oncol       Date:  2010-07       Impact factor: 41.316
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.